The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB),
including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB
correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system.
Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly
prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.
508 - If exacerbation rates are provided in a publication with other details with which NNTs can be calculated, would PAAB allow us to promote the NNTs?
-
The NNT is the estimated average number of patients who need to be treated to prevent one additional bad outcome (e.g. death, hospitalization). An NNT which is calculated by the manufacturer may be included in the APS provided the published paper conveys a statistically significant improvement in the corresponding absolute risk reduction (with multiplicity adjustments performed when required to manage risk of type I error).
The number needed to treat is the mathematical inverse of the absolute risk reduction (i.e. 1 divided by the absolute risk reduction). Note that the absolute risk reduction is the control event rate minus the experimental event rate.
